Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.

Jessica Fleming,Stephanie L. Pugh,Barbara Fisher,Glenn J. Lesser,David R. Macdonald,Erica Hlavin Bell,Joseph P. McElroy,Aline Paixão Becker,Cynthia D Timmers,Kenneth Aldape,C.Leland Rogers,Thomas J. Doyle,Maria Werner-Wasik,Jean-Paul Bahary,Hsiang-Hsuan Michael Yu,David DSouza,Nadia N. Laack,Penny K. Sneed,Young Kwok,Minhee Won,Minesh P. Mehta,Arnab Chakravarti

Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.

2021

PURPOSEThis study sought to determine the prognostic significance of the WHO-defined glioma molecular subgroups along with additional alterations, including MGMT promoter methylation and mutations ...

Keywords:

Oncology
Grade II Glioma
Glioma
promoter methylation
Internal medicine
Phases of clinical research
Medicine
Temozolomide

Correction
Source
Cite
Save

References

Citations